Pilot Clinical Investigation of Risperidone in the Treatment of Psychotic Patients
| Autor: | Vanden Bussche G, Heylen Sl, Reyntjens Aj, Janssen Pa, Gelders Yg |
|---|---|
| Rok vydání: | 1990 |
| Předmět: |
Adult
Male Psychosis medicine.medical_specialty Adolescent medicine.medical_treatment Pilot Projects Antiparkinson medication Piperidines Internal medicine Brief Psychiatric Rating Scale medicine Humans Pharmacology (medical) Antipsychotic Aged Risperidone business.industry Therapeutic effect Isoxazoles General Medicine Middle Aged medicine.disease Psychiatry and Mental health Psychotic Disorders Schizophrenia Anesthesia Clinical Global Impression Drug Evaluation Female business Antipsychotic Agents medicine.drug |
| Zdroj: | Pharmacopsychiatry. 23:206-211 |
| ISSN: | 1439-0795 0176-3679 |
| DOI: | 10.1055/s-2007-1014509 |
| Popis: | Sixty-one adult psychotic patients were treated for four weeks in an open dose-finding study with the new combined serotonin-dopamine antagonist risperidone (R 64 766). Risperidone had a rapid onset of action; a highly significant decrease in the total score on the Brief Psychiatric Rating Scale (BPRS) was already noticed after the first week of treatment. There was also a significant decrease in score for individual BPRS items related to positive, negative, and affective symptoms. In spite of the withdrawal of antiparkinson medication at selection, a significant decrease in extra-pyramidal symptoms (EPS) was observed, as assessed on the Simpson and Angus Scale. The Clinical Global Impression of therapeutic effect was consistent with the BPRS scores, showing a constant improvement throughout the study. The mean daily dose of risperidone at the end of the study was 3.7 mg. Tolerance was excellent and only mild side-effects were reported. Vital signs, ECG-parameters, and laboratory values remained within normal limits. This study demonstrates that risperidone has great potential as an effective and well-tolerated alternative for the treatment of chronically psychotic patients. It has potent antipsychotic effects, a low EPS-inducing profile, and, at the same time, it improves the negative and affective symptoms of schizophrenia. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|